Journal of Interventional Cardiac Electrophysiology

, Volume 23, Issue 2, pp 111–115

Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter

  • Javier E. Banchs
  • Deborah L. Wolbrette
  • Soraya M. Samii
  • Erica D. Penny-Peterson
  • Parag P. Patel
  • Sallie K. Young
  • Mario D. Gonzalez
  • Gerald V. Naccarelli
Article

DOI: 10.1007/s10840-008-9290-6

Cite this article as:
Banchs, J.E., Wolbrette, D.L., Samii, S.M. et al. J Interv Card Electrophysiol (2008) 23: 111. doi:10.1007/s10840-008-9290-6

Abstract

Background

Dofetilide, an IKr blocker has been demonstrated to be effective in terminating persistent atrial fibrillation and flutter (AF/AFL), and in maintaining sinus rhythm after direct current cardioversion (CV). It is not known, however, whether pharmacological conversion with dofetilide predicts maintenance of sinus rhythm. In addition, there is limited information comparing the efficacy of dofetilide in persistent versus paroxysmal AF/AFL.

Methods and Results

Eighty consecutive patients with AF/AFL (51 persistent, 29 paroxysmal) admitted for initiation of dofetilide were studied. Termination of persistent AF/AFL occurred in 61% of patients while 39% required CV. After 21 ± 19 months of follow-up, 37% of patients with persistent AF/AFL were free of recurrence. Acute conversion with dofetilide did not predict long term efficacy. Dofetilide was more effective in maintaining sinus rhythm in patients with AFL (65%) than in those with AF (25%) (p < 0.05). Dofetilide was more likely to maintain sinus rhythm in patients with persistent than paroxysmal AF/AFL (37 vs. 14%; p < 0.05). Torsades de Pointes developed in two patients despite careful dosing and monitoring of QT changes.

Conclusions

Dofetilide is more effective in patients with persistent than in those with paroxysmal AF/AFL. Importantly, short-term response does not necessarily predict long-term efficacy. Significant proarrhythmia can occur even with careful in-hospital monitoring.

Keywords

Atrial fibrillation Dofetilide Antiarrhythmic drugs 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Javier E. Banchs
    • 1
  • Deborah L. Wolbrette
    • 1
  • Soraya M. Samii
    • 1
  • Erica D. Penny-Peterson
    • 1
  • Parag P. Patel
    • 1
  • Sallie K. Young
    • 2
  • Mario D. Gonzalez
    • 1
  • Gerald V. Naccarelli
    • 1
  1. 1.Penn State Heart and Vascular Institute, Milton S. Hershey Medical CenterPenn State UniversityHersheyUSA
  2. 2.Department of PharmacyPenn State UniversityHersheyUSA

Personalised recommendations